|                           | Baseline | 12 weeks |
|---------------------------|----------|----------|
| **MELD score**            |          |          |
| Number of patients        | 5        | 5        |
| Mean ± standard deviation | 6.8±4.9  | 7.2±4.9  |
| **Child-Pugh score**      |          |          |
| Number of patients        | 5        | 5        |
| Mean ± standard deviation | 6.0±0.7  | 6.2±0.8  |
| **Fibroscan (kPa)**       |          |          |
| Number of patients        | 5        | 5        |
| Mean ± standard deviation | 21.92±12.53 | 22.36±13.05 |
| **ELF score**             |          |          |
| Number of patients        | 5        | 5        |
| Mean ± standard deviation | 1.060±0.924 | 1.142±1.277 |

Supplementary Table 1. Change in MELD score, CP score, liver stiffness measure, and ELF score from baseline to post-treatment.
| Inspection item | Upper limit of reference value | Observation period |
|-----------------|------------------------------|--------------------|
|                 |                              | C4D4   | C5D1  | C5D4  | C6D1  | C6D4  | C7D1  | C7D4  | C8D1  |
| ALT (U/L)       | 42 (3 times: 126)            | 49     | 74    | 124   | 75    | 53    | 189   | 95    | 188   |
| AST (U/L)       | 30 (3 times: 90)             | 52     | 65    | 103   | 55    | 45    | 127   | 53    | 128   |
| T.Bil (mg/dL)   | 1.5 (2 times: 3.0)           | 0.7    | 0.9   | 0.7   | 0.9   | 1     | 1.1   | 1     | 1.1   |
| GGT (U/L)       | 64                            | 64     | 66    | 68    | 64    | 61    | 69    | 64    | 67    |
| ALP (U/L)       | 322                           | 324    | 331   | 364   | 338   | 332   | 324   | 329   | 313   |

C: cycle; D: day

Supplementary Table 2. Change in liver related function data after administration (P101-05)